Untitled case

Case Overview — Helsinn Healthcare S.A. et al. v. Eurohealth International Sarl (formerly v. Ben Venue Laboratories, Inc. d/b/a Bedford Laboratories), C.A. No. 13-1612-GMS (D. Del.)

Parties and what they do. The plaintiffs are Helsinn Healthcare S.A., a privately held Swiss specialty pharmaceutical company based in Lugano, and Roche Palo Alto LLC, a Roche affiliate (successor to Syntex USA) that co-owns the asserted formulation patents. Helsinn holds NDA No. 021372 for Aloxi® (palonosetron hydrochloride injection), a 5-HT₃ receptor antagonist used to prevent chemotherapy-induced nausea and vomiting; Aloxi is commercialized in the U.S. by Helsinn's marketing partner Eisai Inc. Notably, this is a brand-vs-generic Hatch-Waxman case, not an NPE/PAE assertion — the plaintiffs are the innovator and its co-owner, asserting Orange Book–listed formulation patents against an ANDA filer. The original defendant, Ben Venue Laboratories, Inc. d/b/a Bedford Laboratories, was an Ohio contract manufacturer of generic injectables and a Boehringer Ingelheim subsidiary. Effective July 15, 2014, Ben Venue divested ANDA No. 205048; the parties stipulated (and the court ordered) that Eurohealth International Sarl be substituted as the ANDA owner and West-Ward Pharmaceutical Corp. as its U.S. agent, so the case continued against Eurohealth/West-Ward and Ben Venue was dismissed without prejudice. (CourtListener docket for 1:13-cv-01612; Stipulation and Order to Substitute Parties, D.I. 98/99 filed Oct. 2014.)

Accused product and patents. The accused conduct is the submission of ANDA No. 205048 with a Paragraph IV certification seeking FDA approval to market a generic 0.25 mg/5 mL palonosetron hydrochloride intravenous solution (bioequivalent to Aloxi) before the listed patents expire. The complaint filed Sept. 25, 2013 asserted the '724, '725, '424, and '981 patents; a June 2014 stipulation added the '218 and '219 patents, and an October 2014 amendment added the newly issued '094 patent while dropping the '218 and '981 claims with prejudice. The case metadata lists only U.S. Patent No. 7,960,424, which is the flagship patent DrugPatentWatch indexes to this docket (drugpatentwatch.com, litigation for Patent 7,960,424), but the docket shows the case actually turned on a family of six patents. All are titled "Liquid Pharmaceutical Formulations of Palonosetron." The '424 patent (issued June 14, 2011; inventors Calderari et al.; priority dating to 2003/2004, so pre-AIA; expiration Jan. 30, 2024) claims a shelf-life-stable liquid/injectable palonosetron formulation with a chelating agent and pH-adjusting acid component — essentially the commercial Aloxi IV solution. The companion patents ('724, '725, '981, '218, '219, '094) claim related stable palonosetron formulations and dosing (the '219 covers a fixed 0.25 mg/5 mL dose).

Posture, venue, and significance. The case was filed in the District of Delaware — the leading Hatch-Waxman venue — because Ben Venue was a Delaware corporation, submitted the ANDA to FDA with an eye to Delaware sales, and consented to jurisdiction. It was assigned to Judge Gregory M. Sleet and consolidated for pretrial purposes with the parallel Aloxi cases, with C.A. No. 13-688-GMS (Aurobindo/Cipla) as the lead case (all four related Delaware actions — 13-688, 13-1612, 13-2101, and 14-427 — were consolidated, and later filings went only in 13-688). Substantive activity included a Markman hearing on Feb. 18, 2015, claim-construction briefing on terms like "pharmaceutically stable" and the '219 preamble, and Helsinn's successful motion to dismiss Cipla's declaratory-judgment counterclaims for lack of subject-matter jurisdiction. The case was terminated on Oct. 27, 2015, with the FJC IDB recording the disposition as "Settled" — contemporaneous with Helsinn's Oct. 13, 2015 announcement of a settlement with Dr. Reddy's permitting a generic Aloxi launch on Sept. 30, 2018 (Helsinn press release; FJC IDB via CourtListener). The precise terms of the Eurohealth/West-Ward resolution are not in public documents I could verify, so I'd flag that as unsourced.

This case matters less on its own than as one thread in the Aloxi/palonosetron patent campaign — Helsinn sued roughly fifteen-plus ANDA sponsors, and the same patent family produced the Supreme Court's Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., 586 U.S. 731 (Jan. 22, 2019), which held that a confidential commercial sale can trigger the AIA's on-sale bar. That on-sale-bar holding arose from the '219 patent in the D.N.J. Teva/Sandoz/Dr. Reddy's litigation (C.A. 2:11-cv-03962), not from this Delaware case; because the '424 patent here is pre-AIA, its validity would have been governed by Pfaff v. Wells Electronics (1998) rather than the AIA provision at issue in the Supreme Court. The companion Delaware cases also generated a notable claim-construction discussion of "pharmaceutically stable" formulations, and the broader litigation illustrates the standard Hatch-Waxman pattern of early settlements with later-arriving generics (Aurobindo, Accord, Sagent, Fresenius, etc.) alongside the Teva "at-risk" launch in 2018.

I'll research this case thoroughly. Let me start with several parallel searches.

Let me pull the docket and related case details.

I'll research this case systematically, starting with identifying the docket and defendant.

Case confirmed: Helsinn Healthcare S.A. v. Ben Venue Labs. (later Eurohealth/West-Ward), consolidated palonosetron cases before Judge Sleet. Now let me find counsel of record.

Found Delaware filings by Morris Nichols (Blumenfeld/Noreika). Let me confirm the full counsel roster in the consolidated Delaware actions and check for the "Of Counsel" firms.

Plaintiffs' Counsel of Record — Helsinn Healthcare S.A. et al. v. Ben Venue Laboratories, Inc. d/b/a Bedford Laboratories, C.A. No. 13-1612-GMS (D. Del.)

Case orientation (first, because it drives the counsel analysis): This was the palonosetron (Aloxi®) Hatch‑Waxman group of cases in Delaware. 13‑1612 was filed 9/25/2013 against Ben Venue/Bedford (ANDA No. 205048); Ben Venue was later substituted out and replaced by Eurohealth International Sarl and West‑Ward Pharmaceutical Corp. (stipulation to substitute parties, entered in the consolidated lead case 13‑688‑GMS, D.I. 99 — RECAP PDF). The Delaware palonosetron actions (13‑688‑GMS, 13‑1612‑GMS, 13‑2101‑GMS, 14‑427‑GMS) were consolidated before Chief Judge Gregory M. Sleet. The case terminated 10/27/2015, FJC disposition "Settled." (CourtListener docket 4220292; FJC IDB record)

Attorneys appearing on the Delaware docket for Plaintiffs (Helsinn Healthcare S.A. and Roche Palo Alto LLC)

1. Jack B. Blumenfeld — Delaware counsel of record (the attorney who actually signed/filed Plaintiffs' papers in D. Del.)

• Firm/office: Morris, Nichols, Arsht & Tunnell LLP, 1201 N. Market Street, Wilmington, DE (jblumenfeld@mnat.com).
• Appearance basis: Signed the scheduling-order transmittal letter to Judge Sleet and Plaintiffs' joint stipulations in 13‑1612; the consolidated plaintiffs' briefing (13‑688 D.I. 119, Dec. 5, 2014) bears his signature block as "Attorneys for Plaintiffs Helsinn Healthcare S.A. and Roche Palo Alto LLC." (RECAP PDF; 13‑1612 D.I. 27 RECAP PDF)
• Note: Long-time dean of the Delaware patent bar; Delaware counsel in a very large number of Hatch‑Waxman/ANDA matters. This is the practical "lead" Delaware counsel of record for Plaintiffs in this case.

2. Maryellen Noreika — Delaware counsel of record

• Firm/office: Morris, Nichols, Arsht & Tunnell LLP, Wilmington, DE (mnoreika@mnat.com).
• Appearance basis: Filed Plaintiffs' answers to counterclaims and notices of service in 13‑1612 (e.g., docket entries 23, 25, 28 on the CourtListener docket), and is co-signed on the consolidated plaintiffs' filings.
• Note: Morris Nichols IP partner at the time; she was later confirmed as a U.S. District Judge for the District of Delaware (2018) — and has since handled D. Del. ANDA cases from the bench.

3. Mark E. Waddell — "Of Counsel" for plaintiff Helsinn Healthcare S.A. (non-Delaware)

• Firm/office: Loeb & Loeb LLP, 345 Park Avenue, New York, NY.
• Appearance basis: Listed as "Attorneys for Plaintiff Helsinn Healthcare S.A." in the stipulated consolidation extension filed in 13‑1612 (D.I. 27) — the same firm/attorney appears for Helsinn across the parallel palonosetron suits.
• Note: Life‑sciences/IP litigator; part of Helsinn's national palonosetron team.

Additional attorneys in the Helsinn palonosetron campaign — caution on scope

The Paul Hastings LLP team appears repeatedly as "Of Counsel" for Helsinn Healthcare S.A. in this patent family: Joseph M. O'Malley, Jr.; Bruce M. Wexler; Eric W. Dittmann; David M. Conca; Gary Ji; Angela C. Ni (Paul Hastings LLP, 75 East 55th Street, New York, NY), alongside Saul Ewing LLP (Charles M. Lizza, William C. Baton, Newark, NJ) as local counsel. However, the documents I could verify with those signature blocks are from the parallel New Jersey actions (Helsinn v. Dr. Reddy's, No. 11‑3962; the '981/'094 complaints against Teva/Sandoz; Helsinn v. Hospira), not from the Delaware 13‑1612 docket. I could not confirm from retrieved Delaware filings that Paul Hastings (or Saul Ewing) entered a Delaware appearance in C.A. No. 13‑1612. Treat their Delaware participation as unverified; they should be described as Helsinn's national/New Jersey counsel unless a Delaware pro hac vice entry is pulled from PACER.

• Charles M. Lizza (Saul Ewing) is worth flagging on experience: he was Helsinn's trial counsel in the D.N.J. Aloxi® wins against Teva and Dr. Reddy's — the Teva case produced the Supreme Court decision in Helsinn Healthcare S.A. v. Teva Pharms. USA, Inc., 586 U.S. 731 (2019) (on‑sale bar, unanimous) — but that was New Jersey, not Delaware. (Saul Ewing bio)

Explicit gaps / caveats

• No in‑house counsel identified. I found no public record naming Helsinn or Roche Palo Alto in‑house counsel appearing in C.A. No. 13‑1612. I will not guess a name.
• No merits opinion exists in this docket (FJC disposition: "Settled"; terminated 10/27/2015), so there is no opinion identifying "lead trial counsel."
• Pro hac vice entries not retrieved. Individual D.I. entries for Plaintiffs' pro hac vice motions (if any) were not pulled; the docket is partly paywalled on PACER, and my retrieval relied on CourtListener/RECAP and secondary sources. Additional out‑of‑state counsel could exist on the docket beyond Blumenfeld, Noreika, and Waddell.
• Roche Palo Alto LLC was a co-plaintiff and assignee (Syntex/Roche legacy rights); the Delaware filings style the Morris Nichols attorneys as appearing for both Helsinn and Roche Palo Alto, and I found no separate Roche-specific Delaware counsel.

Bottom line: For C.A. No. 13‑1612‑GMS itself, the verifiable counsel of record for the plaintiffs are Jack B. Blumenfeld and Maryellen Noreika of Morris, Nichols, Arsht & Tunnell LLP (Wilmington, DE) as Delaware counsel, with Mark E. Waddell (Loeb & Loeb, New York) listed of counsel for Helsinn. Helsinn's broader palonosetron team (Paul Hastings and Saul Ewing) was heavily involved in the parallel New Jersey litigations, but I could not verify a Delaware appearance by them in this docket.

I'll research this case to identify the defendant(s) and their counsel of record.

The defendant appears to be Ben Venue Laboratories, Inc. d/b/a Bedford Laboratories, later joined/substituted by Eurohealth International Sarl and West-Ward Pharmaceutical Corp. Let me pull the docket and counsel entries.

Let me examine the actual filings to identify defense counsel (local and of counsel).

Defendant(s) and defense counsel — Helsinn Healthcare S.A. v. Ben Venue Laboratories, Inc., C.A. No. 1:13-cv-01612-GMS (D. Del.)

Who the defendants were

The case as filed on Sept. 25, 2013 named a single defendant: Ben Venue Laboratories, Inc. d/b/a Bedford Laboratories (the injectables unit of Boehringer Ingelheim). The complaint asserted the '724, '725, '424 and '981 patents against Ben Venue's ANDA No. 205048 for generic 0.25 mg/5 mL palonosetron HCl IV solution (Helsinn's Aloxi®). See Complaint, D.I. 1; CourtListener docket 4220292.

The docket caption was later changed to Helsinn Healthcare SA v. Eurohealth International Sarl because, by stipulation and order entered in the consolidated lead case (C.A. No. 13-688-GMS, D.I. 98–99, filed Oct. 16–17, 2014), Eurohealth International Sarl and West-Ward Pharmaceutical Corp. were substituted for Ben Venue as defendants, and Ben Venue was dismissed without prejudice under Rule 41(a)(1)(A)(ii). Ben Venue had divested all rights in ANDA No. 205048 effective July 15, 2014. (Eurohealth and West-Ward are Hikma entities.) Case No. 13-1612 was consolidated for all purposes into 13-688-GMS. The action terminated Oct. 27, 2015.

Counsel of record for the defense

Local counsel — Shaw Keller LLP (Wilmington, DE)

Their appearance is documented in the Oct. 17, 2014 Stipulation and Order to Substitute Parties (D.I. 99 in 13-688-GMS / 13-1612-GMS), which is expressly signed "Attorneys for Defendants Ben Venue, Eurohealth International Sarl, and West-Ward Pharmaceutical Corp.," and in the answer/counterclaims at D.I. 24 (Feb. 24, 2014), signed by Ms. Keller.

National/lead counsel — Kenyon & Kenyon LLP (listed as "OF COUNSEL" per Delaware convention)

Kenyon & Kenyon was a long-established IP boutique (founded 1879) that dissolved in 2016, with much of its practice moving to Andrews Kurth (later Hunton Andrews Kurth). (General background, not sourced to a docket entry.)

Caveats and what I could not confirm

• I could not retrieve a pro hac vice motion or the initial Rule 12/answer signature block for Ben Venue from the free RECAP docket, so I cannot verify whether additional Kenyon attorneys were admitted pro hac vice or who signed the first answer (D.I. 10 area). The counsel above are those affirmatively named in the stipulations/orders that RECAP reproduces.
• No individual in-house attorney appeared of record in the materials I reviewed.
• It is unclear from the public docket whether Kenyon & Kenyon continued to represent the Hikma successor entities (Eurohealth/West-Ward) after the October 2014 substitution, or whether successor counsel took over the consolidated defense; no separate notice of appearance was surfaced.
• Because 13-1612 was consolidated into 13-688-GMS, many later filings (claim construction, etc.) appear only in the 13-688 docket. Any counsel appearing solely there post-consolidation would not be captured in my review of the 13-1612 docket.
• Nothing in this case appears to have been sealed as to counsel identity; the limitation is the partial free-RECAP coverage, not sealing.